
|Articles|November 1, 2003
Vitrase results presented at retinal society meeting
Irvine, CA -- Two phase III clinical trials of ovine hyaluronidase (Vitrase, ISTA Pharmaceuticals) reveal a statistically significant reduction in vitreous hemorrhage density in patients with diabetes during each of 3 months following a single intravitreous injection of ovine hyaluronidase when compared with a single injection of saline solution.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
2
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
3
Opuviz aflibercept biosimilar launches in Europe for retinal diseases
4
Study links alcohol consumption to earlier advanced presbyopia in men
5





















